1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol has been researched along with levodopa in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gilgun-Sherki, Y; Mechoulam, R; Melamed, E; Offen, D | 1 |
Dowd, E; Finn, DP; Gorman, AM; Walsh, S | 1 |
2 other study(ies) available for 1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol and levodopa
Article | Year |
---|---|
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Apomorphine; Cannabinoids; Carbidopa; Cell Line, Tumor; Dronabinol; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rotation; Substantia Nigra | 2003 |
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |